111 related articles for article (PubMed ID: 11766744)
1. The importance of serum insulin-like growth factor-I level determination in the follow-up of patients with epithelial ovarian cancer.
Bese T; Nomir SK
Eur J Gynaecol Oncol; 2001; 22(5):372-6. PubMed ID: 11766744
[TBL] [Abstract][Full Text] [Related]
2. Significance of serum c-erbB-2 oncoprotein, insulin-like growth factor-1 and vascular endothelial growth factor levels in ovarian cancer.
Akcay T; Yasar O; Kuseyri MA; Dincer Y; Aydinli K; Benian A; Balcan E; Erenel H
Bratisl Lek Listy; 2016; 117(3):156-60. PubMed ID: 26925746
[TBL] [Abstract][Full Text] [Related]
3. Serum insulin-like growth factor (IGF)-I, IGF binding protein (IGFBP)-3, leptin concentrations and insulin resistance in benign and malignant epithelial ovarian tumors in postmenopausal women.
Serin IS; Tanriverdi F; Yilmaz MO; Ozcelik B; Unluhizarci K
Gynecol Endocrinol; 2008 Mar; 24(3):117-21. PubMed ID: 18335323
[TBL] [Abstract][Full Text] [Related]
4. The value of serum bcl-2 levels in advanced epithelial ovarian cancer.
Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
Med Oncol; 2006; 23(2):213-7. PubMed ID: 16720921
[TBL] [Abstract][Full Text] [Related]
5. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer.
Onsrud M; Shabana A; Austgulen R
Tumour Biol; 1996; 17(2):90-6. PubMed ID: 8658018
[TBL] [Abstract][Full Text] [Related]
6. Estimation of the usefulness of neoplastic markers TPS and CA 125 in diagnosis and monitoring of ovarian cancer.
Zygmunt A; Madry R; Markowska J; Fischer Z
Eur J Gynaecol Oncol; 1999; 20(4):298-301. PubMed ID: 10475127
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of human epididymis protein 4 in epithelial ovarian cancer.
Paek J; Lee SH; Yim GW; Lee M; Kim YJ; Nam EJ; Kim SW; Kim YT
Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):338-42. PubMed ID: 21683503
[TBL] [Abstract][Full Text] [Related]
8. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors.
Candido Dos Reis F; Moreira de Andrade J; Bighetti S
Gynecol Obstet Invest; 2002; 54(3):132-6. PubMed ID: 12571433
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of whether serum tumor markers in patients with epithelial ovarian carcinoma change following chemotherapy.
Li XP; Xu QY; Wang JL; Wang SJ; Zhao Y; Wei LH
Chin Med J (Engl); 2012 Feb; 125(3):410-5. PubMed ID: 22490394
[TBL] [Abstract][Full Text] [Related]
10. [Evaluation of selected serum protein markers as early detectors of ovarian cancer].
Mrochem J; Sodowski K; Deja R; Walaszek-Gruszka A; Wojcieszek A; Kołosza Z; Chmura A; Czernik E; Masłyk B; Bartnik W; Cnota W
Ginekol Pol; 2008 Apr; 79(4):271-5. PubMed ID: 18592865
[TBL] [Abstract][Full Text] [Related]
11. Elevated serum insulin-like growth factor-binding protein 2 (IGFBP-2) and decreased IGFBP-3 in epithelial ovarian cancer: correlation with cancer antigen 125 and tumor-associated trypsin inhibitor.
Flyvbjerg A; Mogensen O; Mogensen B; Nielsen OS
J Clin Endocrinol Metab; 1997 Jul; 82(7):2308-13. PubMed ID: 9215312
[TBL] [Abstract][Full Text] [Related]
12. Serum CA 125 Level after Neoadjuvant Chemotherapy is Predictive of Prognosis and Debulking Surgery Outcomes in Advanced Epithelial Ovarian Cancer.
Matsuhashi T; Takeshita T; Yamamoto A; Kawase R; Yamada T; Kurose K; Doi D; Konnai K; Onose R; Kato H
J Nippon Med Sch; 2017; 84(4):170-176. PubMed ID: 28978897
[TBL] [Abstract][Full Text] [Related]
13. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Int J Gynecol Cancer; 2001; 11(4):277-82. PubMed ID: 11520365
[TBL] [Abstract][Full Text] [Related]
14. Platelet-derived growth factor receptor beta serum concentrations during first-line therapy in ovarian cancer.
Mathey S; Graeser MK; Zu Eulenburg C; Woelber L; Trillsch F; Jaenicke F; Müller V; Milde-Langosch K; Mahner S
Oncology; 2013; 85(2):69-77. PubMed ID: 23860180
[TBL] [Abstract][Full Text] [Related]
15. Serum soluble Fas levels and prediction of response to platinum-based chemotherapy in epithelial ovarian cancer.
Chaudhry P; Srinivasan R; Patel FD; Gopalan S; Majumdar S
Int J Cancer; 2008 Apr; 122(8):1716-21. PubMed ID: 18092329
[TBL] [Abstract][Full Text] [Related]
16. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma.
Diamandis EP; Scorilas A; Fracchioli S; Van Gramberen M; De Bruijn H; Henrik A; Soosaipillai A; Grass L; Yousef GM; Stenman UH; Massobrio M; Van Der Zee AG; Vergote I; Katsaros D
J Clin Oncol; 2003 Mar; 21(6):1035-43. PubMed ID: 12637468
[TBL] [Abstract][Full Text] [Related]
17. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.
Mok SC; Chao J; Skates S; Wong K; Yiu GK; Muto MG; Berkowitz RS; Cramer DW
J Natl Cancer Inst; 2001 Oct; 93(19):1458-64. PubMed ID: 11584061
[TBL] [Abstract][Full Text] [Related]
18. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
Gadducci A; Cosio S; Fanucchi A; Negri S; Cristofani R; Genazzani AR
Gynecol Oncol; 2004 Apr; 93(1):131-6. PubMed ID: 15047226
[TBL] [Abstract][Full Text] [Related]
19. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of rising serum CA-125 levels within the normal range in patients with epithelial ovarian, primary peritoneal, and tubal cancers, who, after initial treatment, had a complete clinical response.
Levy T; Weiser R; Boaz M; Shem EB; Golan A; Menczer J
Int J Gynecol Cancer; 2012 Oct; 22(8):1344-8. PubMed ID: 22954785
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]